|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:alsoKnownAs
|
gptkb:rifampicin
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:J04AB02
|
|
gptkbp:category
|
gptkb:antineoplastic_agent
gptkb:antibiotic
antimycobacterial
|
|
gptkbp:chemicalFormula
|
C43H58N4O12
|
|
gptkbp:combinationTherapy
|
gptkb:isoniazid
gptkb:ethambutol
gptkb:pyrazinamide
streptomycin
|
|
gptkbp:contraindication
|
gptkb:liver_disease
|
|
gptkbp:discoveredBy
|
gptkb:Gabriele_Timbal
gptkb:Piero_Sensi
|
|
gptkbp:discoveredIn
|
1965
|
|
gptkbp:drugInteraction
|
induces cytochrome P450 enzymes
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:lactationUse
|
use with caution
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA-dependent RNA polymerase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
822.94 g/mol
|
|
gptkbp:origin
|
derived from rifamycin B
|
|
gptkbp:pregnancyCategory
|
C
use with caution
|
|
gptkbp:producedBy
|
gptkb:Amycolatopsis_mediterranei
|
|
gptkbp:resistantTo
|
mutation in rpoB gene
|
|
gptkbp:riskFactor
|
drug resistance if used alone
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
hepatotoxicity
gastrointestinal upset
flu-like syndrome
hypersensitivity reactions
orange discoloration of body fluids
|
|
gptkbp:spectrumOfActivity
|
gptkb:Haemophilus_influenzae
gptkb:Neisseria_meningitidis
gptkb:Mycobacterium_tuberculosis
gptkb:Staphylococcus_aureus
|
|
gptkbp:usedFor
|
gptkb:MRSA_infections
tuberculosis
leprosy
meningococcal prophylaxis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:NNRTIs
gptkb:fluconazole
gptkb:Prograf
gptkb:Harvoni
gptkb:sofosbuvir
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rifampin
|